INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Diclofenac Sodium Transdermal Patches for Primary Dysmenorrhea: Formulation Strategies, Skin Permeation, and Evidence Gaps

Vedika Hangargi*, Sakshi Suvarna, Farha Ansari, Allen Mokle, Shraddha Joshi

chhatrapati shivaji maharaj university, Panvel-410221.

ARTICLE INFO

Published: 25 Nov 2026
Keywords:
Diclofenac sodium, Transdermal drug delivery, Primary dysmenorrhea
DOI:
10.5281/zenodo.24528241

ABSTRACT

Dysmenorrhea is a common menstrual disorder characterized by cramping pelvic pain that is frequently associated with elevated prostaglandin activity and uterine contractions. Oral non-steroidal anti-inflammatory drugs are commonly used for symptom relief; however, gastrointestinal intolerance, repeated dosing requirements, and systemic exposure may affect acceptability in some patients. Transdermal drug delivery systems have therefore attracted interest as an alternative route for delivering analgesic and anti-inflammatory agents. Diclofenac sodium, a cyclooxygenase-inhibiting non-steroidal anti-inflammatory drug, has been investigated in experimental transdermal formulations using polymeric matrices, plasticizers, and chemical permeation enhancers. This review critically discusses the formulation approaches, excipient functions, manufacturing methods, evaluation parameters, and potential therapeutic relevance of diclofenac transdermal patches for primary dysmenorrhea. Particular attention is given to hydroxypropyl methylcellulose, polyvinylpyrrolidone, propylene glycol, and sodium lauryl sulfate, as well as to solvent-casting methods and physicochemical characterization. Evidence from related pain indications is considered separately from evidence directly related to dysmenorrhea. The available literature indicates that diclofenac transdermal systems are technically feasible, but direct clinical evidence supporting their use specifically for menstrual pain remains insufficient. Future research should prioritize standardized in vitro release and skin- permeation studies, pharmacokinetic characterization, irritation testing, formulation optimization, and well-designed clinical trials in individuals with primary dysmenorrhea. The review identifies the gap between formulation feasibility and clinical validation and proposes research directions for the development of patient-centered transdermal systems.

***Corresponding Author:** Vedika Hangargi
Address: chhatrapati shivaji maharaj university, Panvel-410221
Email ✉: vedika.hangargi@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

INTRODUCTION

Primary dysmenorrhea refers to painful menstruation in the absence of an identifiable pelvic pathology. The pain is commonly associated with increased endometrial prostaglandin production, which promotes uterine hypercontractility, reduced uterine blood flow, and the generation of pelvic cramping. Symptoms may extend to the lower back and thighs and may be accompanied by nausea, fatigue, headache, or gastrointestinal discomfort. Non-steroidal anti-inflammatory drugs are widely used because they inhibit cyclooxygenase-mediated prostaglandin synthesis. Oral administration is effective for many patients, but repeated dosing may be associated with gastrointestinal adverse effects, systemic exposure, and adherence challenges. These limitations have encouraged interest in alternative delivery routes. Transdermal drug delivery systems administer an active pharmaceutical ingredient across the skin into local tissues or the systemic circulation. Potential advantages include avoidance of gastrointestinal degradation, partial avoidance of hepatic

Diclofenac sodium is used for the management of pain and inflammation in several clinical settings. Its mechanism involves inhibition of cyclooxygenase and a consequent reduction in prostaglandin synthesis. Conventional systemic first-pass metabolism, prolonged drug input, and the possibility of reducing dosing frequency. Nevertheless, the skin—particularly the stratum corneum—represents a substantial barrier. Successful transdermal delivery depends on drug physicochemical properties, formulation composition, patch design, adhesive performance, and the use of suitable permeation-enhancement strategies. Diclofenac sodium is a non-steroidal anti-inflammatory drug that reduces prostaglandin synthesis through cyclooxygenase inhibition. Although diclofenac-containing topical and transdermal products have been studied for several pain conditions, evidence from other indications cannot automatically be interpreted as evidence of efficacy in dysmenorrhea. The purpose of this review is therefore to examine the formulation science of diclofenac transdermal patches and to assess their potential relevance to primary dysmenorrhea while clearly identifying current evidence limitations. The pathophysiology of primary dysmenorrhea is strongly associated with increased prostaglandin activity during menstruation. Prostaglandins contribute to myometrial contraction and vasoconstriction, which may result in uterine ischemia and pain. The clinical severity of dysmenorrhea varies between individuals and may be influenced by age, menstrual characteristics, psychosocial factors, and coexisting conditions. Because prostaglandins are important mediators of menstrual pain, cyclooxygenase inhibition provides a pharmacological rationale for the use of NSAIDs. However, the pharmacological rationale alone does not establish that a particular transdermal formulation will provide adequate drug delivery, a sufficiently rapid onset, or clinically meaningful pain relief. The objective of this review is to summarize and critically discuss published information on diclofenac sodium transdermal patch formulation, including polymer selection, plasticizers, penetration enhancers, manufacturing methods, patch architecture, physicochemical evaluation, drug-release testing, skin-permeation assessment, and therapeutic considerations relevant to primary dysmenorrhea. The review distinguishes direct evidence involving diclofenac sodium formulations from indirect evidence involving diclofenac salts, other NSAIDs, or unrelated pain indications. Claims concerning clinical efficacy, safety, pharmacokinetics, and reduced systemic adverse effects should be interpreted according to the population, formulation, comparator, and outcome reported in the original study.

2. OBJECTIVE AND REVIEW SCOPE

3. PATHOPHYSIOLOGY OF PRIMARY DYSMENORRHEA

4. DICLOFENAC SODIUM AND THE RATIONALE FOR TRANSDERMAL DELIVERY

Chemical permeation enhancers are intended to increase drug transport through the stratum corneum. Sodium lauryl sulfate has been investigated as an enhancer because of its surfactant properties. Other enhancer classes include alcohols, glycols, fatty acids, terpenes, and selected surfactants. Enhancer selection requires Polymeric matrices are used to incorporate the drug and control the formation and mechanical properties of the patch. Hydroxypropyl methylcellulose is

frequently investigated because it can form films and modify drug diffusion. Polyvinylpyrrolidone may be used as a hydrophilic co-polymer to influence film formation, drug dispersion, hydration, and release behavior. Ethylcellulose and other polymers may also be considered when a more hydrophobic matrix or altered release profile is required. The ratio and total concentration of polymers can affect patch thickness, flexibility, moisture uptake, mechanical strength, drug diffusion, and the interaction between the drug and the polymeric network. Increasing polymer concentration may increase matrix density and thickness, but the effect on drug release and permeation is formulation-specific and should be demonstrated experimentally rather than assumed.

5.2 Plasticizers

Plasticizers such as propylene glycol are added to improve flexibility and reduce brittleness. They may also influence polymer mobility, water content, drug solubility, and skin permeation. The concentration of plasticizer must be optimized because excessive amounts can alter patch integrity, tack, moisture behavior, or drug-release kinetics.

5.3 Chemical permeation enhancers

administration may produce effective analgesia but can also expose the gastrointestinal, renal, cardiovascular, and other systems to adverse effects, particularly when risk factors or inappropriate dosing are present. A transdermal system may provide a more gradual input of drug and may improve convenience by reducing the need for repeated oral administration. However, transdermal delivery does not eliminate systemic exposure or the class-related risks of diclofenac. The extent of systemic exposure depends on the formulation, application area, duration of use, skin condition, and the amount of drug that crosses the skin. Diclofenac sodium should also be distinguished from diclofenac epolamine and other diclofenac-containing products. Different salts and product designs may have different physicochemical properties, drug loads, release characteristics, and clinical evidence. Results obtained with one product should not be generalized to another without supporting data.

5. FORMULATION STRATEGIES FOR DICLOFENAC TRANSDERMAL PATCHES

5.1 Polymeric matrix systems

Transdermal systems may be classified according to the location of the drug and the mechanism controlling release. Matrix systems disperse the drug within a polymeric layer. Reservoir systems contain the drug in a separate compartment and may use a rate-controlling membrane. Drug-in-adhesive systems incorporate the drug directly into the adhesive layer. Multilayer designs may combine backing layers, drug-containing layers, membranes, adhesives, and release liners. The choice of architecture affects manufacturing complexity, dose uniformity, adhesion, release control, dose dumping risk, and patient acceptability. For a dysmenorrhea application, the desired system would need to provide reproducible delivery, acceptable adhesion during daily activities, low irritation potential, and an onset of relief compatible with the clinical course of menstrual pain. Solvent selection depends on the solubility of the drug and polymers, evaporation characteristics, safety considerations, and compatibility with the manufacturing process. The original draft describes both chloroform–methanol and methanol– water systems. These descriptions must be checked against the original experimental report before publication because the solvent composition is a critical reproducibility parameter and should not be reported inconsistently. Solvent casting is a commonly described laboratory method for preparing polymeric transdermal films. In a typical process, the selected polymers are dissolved or dispersed in a suitable solvent system. The drug, plasticizer, and any permeation enhancer are then incorporated under controlled mixing. The resulting formulation is cast onto a suitable release surface and dried under defined conditions. The dried film is subsequently removed and cut into patches of a predetermined area. Important process variables include mixing time, stirring speed, temperature, solvent ratio, casting volume, drying time, drying temperature, film thickness, and residual-solvent control. These variables can influence drug distribution, film uniformity, mechanical properties, and release behavior. A publication-quality review should report these variables only when they are available in the original source. a balance

between increased permeation and the risk of irritation, barrier disruption, or instability.

5.4 Solvent systems

8. EVALUATION PARAMETERS

8.1 Physical appearance

6. MANUFACTURING METHODS

7. PATCH DESIGN AND STRUCTURAL CLASSIFICATION

Folding endurance provides an indication of film flexibility and resistance to repeated handling. Where possible, tensile strength, percentage elongation, and adhesive performance should also be evaluated because folding endurance alone does not fully describe patch durability.

8.4 Moisture content and moisture uptake

Moisture content and moisture uptake can affect flexibility, stability, microbial risk, drug diffusion, and packaging requirements. The test conditions, humidity, drying agent, duration, and calculation method should be reported precisely.

8.5 Drug-content uniformity

Drug content should be quantified using a validated analytical method, such as UV spectrophotometry or high-performance liquid chromatography, provided that the method is specific and suitable for the formulation matrix. The sampling plan and acceptance criteria should be justified using the applicable standard or the original study protocol.

8.6 In vitro drug release

In vitro release testing is used to characterize the amount of drug released from the patch over time. The apparatus, receptor medium, temperature, agitation conditions, sampling intervals, analytical method, and sink conditions should be specified. Release data may be fitted to kinetic models, but the selected model should be justified and not used as a substitute for mechanistic interpretation.

8.7 In vitro skin permeation

Skin-permeation studies may be conducted using diffusion cells and an appropriate skin membrane. The source and preparation of the skin, receptor medium, temperature, dose applied, sampling schedule, and analytical method are essential for interpretation. Permeation outcomes may include cumulative amount permeated, steady-state flux, lag time, and permeability coefficient.

8.8 Skin irritation and adhesion

Irritation potential should be assessed using ethically approved and scientifically justified methods. Adhesion studies should examine how well the patch remains attached under conditions that simulate normal movement, perspiration, and daily Thickness should be measured at multiple locations using a calibrated micrometer or equivalent instrument. Individual patch weights should be recorded to assess batch consistency. Results should be reported as mean ± standard deviation with the number of samples clearly stated.

8.3 Folding endurance and tensile properties

Films should be examined for color, transparency or opacity, smoothness, flexibility, air bubbles, cracks, crystals, and other visible defects.

8.2 Thickness and weight uniformity

The available material in the present draft includes a formulation report describing diclofenac sodium films prepared using hydroxypropyl methylcellulose, polyvinylpyrrolidone, propylene glycol, and sodium lauryl sulfate. The reported formulation comparison emphasizes changes in thickness, weight, folding endurance, moisture-related properties, and weight uniformity with changes in polymer concentration. The draft also cites a broader review of analgesic transdermal systems that discusses diclofenac-containing patches and transdermal design categories. Because that source is not specific to dysmenorrhea and includes a different diclofenac salt, its findings should be treated as indirect evidence. The pharmacokinetic or clinical behavior of a diclofenac epolamine product cannot be assumed to represent a diclofenac sodium matrix patch. A stronger review should include a structured evidence table with, at minimum, the study citation, diclofenac

form, drug loading, polymer composition, enhancer, patch area, manufacturing method, release conditions, permeation membrane, principal findings, and study limitations. It should also distinguish formulation feasibility from demonstrated therapeutic effectiveness. The rationale for investigating diclofenac transdermal patches in primary dysmenorrhea is biologically plausible because cyclooxygenase inhibition targets a pathway involved in menstrual pain. Nevertheless, dysmenorrhea presents specific development challenges. Pain may require relatively rapid relief, symptoms recur cyclically, and the appropriate dose and duration of transdermal delivery must be established. A patch that releases drug slowly may not provide adequate early analgesia, whereas a formulation designed for rapid delivery may increase irritation or systemic exposure. At present, evidence from postoperative, dental, musculoskeletal, or other pain conditions should be described as supportive or indirect rather than conclusive. The central research question is not simply whether diclofenac can be incorporated into a patch, but whether a specific formulation can deliver an adequate and reproducible amount of drug safely and provide clinically meaningful relief during menstruation. activity. Animal studies, when used, require appropriate ethical approval and should be reported transparently.

8.9 Stability studies

Stability assessment should consider drug content, appearance, mechanical properties, adhesion, residual solvent, and release behavior under defined storage conditions. Packaging should protect the formulation from moisture, light, and other relevant environmental factors.

10. RELEVANCE TO PRIMARY DYSMENORRHEA

9. COMPARATIVE EVIDENCE AND CRITICAL APPRAISAL

CONCLUSION

Diclofenac sodium transdermal patches represent a technically plausible drug-delivery approach for exploring non-oral management of pain associated with primary dysmenorrhea. Polymeric matrices, plasticizers, and chemical permeation enhancers can be used to modify film formation, flexibility, drug release, and skin transport. However, formulation feasibility should not be equated with clinical efficacy. The evidence currently summarized in the draft is insufficient to establish that diclofenac sodium transdermal patches are effective or safer than standard oral NSAID treatment for dysmenorrhea. Further work is required to connect physicochemical performance with skin permeation, pharmacokinetic behavior, tolerability, and patient-centered clinical outcomes. A rigorous evidence base and transparent reporting will be essential before this approach can be considered a validated therapeutic option.

12. FUTURE RESEARCH DIRECTIONS

11. LIMITATIONS OF THE AVAILABLE EVIDENCE

Conduct reproducible in vitro release and skin-permeation studies using standardized methods. Investigate the influence of polymer ratios, plasticizer concentration, and permeation-enhancer type on flux, lag time, and irritation potential. Characterize drug–excipient compatibility using suitable analytical techniques. Assess adhesion, mechanical performance, residual solvents, stability, and packaging compatibility. Perform pharmacokinetic studies where scientifically justified and ethically appropriate. Conduct carefully designed clinical studies in individuals with primary dysmenorrhea before making therapeutic claims. Compare onset of relief, duration of effect, tolerability, adherence, and patient acceptability with established treatment options. The present draft is based on a limited number of identified references and therefore should not be described as a comprehensive systematic review. Many formulation reports emphasize physicochemical characterization without providing detailed skin-permeation, pharmacokinetic, or clinical data. Studies involving different diclofenac salts, dosage forms, or clinical indications may not be directly comparable. Differences in patch area, drug loading, receptor medium, skin model, and analytical methods can substantially affect apparent release and permeation results. Claims concerning reduced adverse effects or improved tolerability require direct comparative

evidence and should not be inferred solely from avoidance of oral administration.

Funding

To be completed by the authors, if applicable.

Author Contributions

To be completed by the authors according to the actual contributions of each author.

1. Sahu GK, et al. Formulation and Evaluation of Diclofenac Sodium Transdermal Patches for

Dysmenorrhea. Acta Scientific Pharmaceutical Sciences. 2024;8 (6):37–43. [Bibliographic details should be checked against the original article.]

2. Sahni H. [Full title and bibliographic details to be verified from the original source].

International Journal of Pharmaceutical Sciences. 2024;2 (5):268–278.

3. Kováčik A, Kopečná M, Vávrová K. Permeation enhancers in transdermal drug delivery:

benefits and limitations. Expert Opin Drug Deliv. 2020;17 (2):145–155. doi :1 0. 108 0/ 174 252 47. 20 20. 17 130 87.

4. Alkilani AZ, McCrudden MTC, Donnelly RF. Transdermal drug delivery: innovative

pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics. 2015;7 (4):438–470. doi:10.3390/pharmaceutics7040438.

5. Alexander A, Dwivedi S, G crowe? [Do not use until author list and bibliographic details

are verified from the original source.] Overcoming skin barriers through advanced transdermal drug delivery approaches. J Control Release. 2022. doi:10.1016/j.jconrel.2022.09.025.

6. Improved topical drug delivery: role of permeation enhancers and advanced approaches.

Pharmaceutics. 2022;14 (12):2818. doi:10.3390/pharmaceutics14122818. [Authors should be retrieved and checked from the original publication before submission.]

7. Comparison of skin permeability for three diclofenac topical formulations: an in vitro

study. [Authors and journal details should be verified from PubMed PMID: 24601219 before submission.]

8. Transdermal drug delivery systems: a focused review of the physical methods of

permeation enhancement. [Authors, journal, year, volume, pages, and DOI should be verified from the original publication.]

9. A review on chemical permeation enhancers used in the formulation of transdermal drug

delivery system. J Pharm Res Int. 2021;33 (59A):429–437. doi :1 0. 973 4/ j pr i/ 2 021/ v 3 3i 59A3 428 8.

DECLARATIONS

Acknowledgment

To be completed by the authors, if applicable.

Conflict Of Interest

The authors should declare any financial, personal, or institutional relationships that could influence the work.

10. Transdermal drug delivery system: a comprehensive review of innovative strategies,

applications, and regulatory perspectives. OnNano. 2025;24:100245. doi:10.1016/j.onano.2025.100245. [Verify complete author list and journal metadata

REFERENCES

1. Goh CF, Lane ME. Formulation of diclofenac for dermal delivery. Int J Pharm.201 4;473 (1 -2):607-6 16. doi:10 .1016 /j.ij pha rm.2 014.0 7.052
2. Hagen M, Baker M. Skin penetration and tissue permeation after topical administration ofdiclofenac. Curr Med Res Opin. 2017;33 (9):1623-1634. doi:10.1080/03007995.2017.1352497.
3. Pradal J, Vallet CM, Frappin G, Bariguian F, Lombardi MS. Importance of the formulation in the skindelivery of topical diclofenac: not all topical diclofenac formulations are the same. J Pain Res. 201 9;12:11 49-115 4. doi:10. 2147/JPR.S1 91300 .
4. Across Barriers et al. Hydrogel increases diclofenac skin permeation and absorption. BiopharmDrug Dispos. 2019;40 (7):217-224. doi:10.1002/bdd.2194.
5. Saghir SA, et al. Transdermal permeation and skin retention of diclofenac andetofenamate/flufenamic acid from over-the-counter pain relief products. J Pharm Sci. 2021. do i:10.1 016/j .x phs .202 1.01. 022.
6. Topical NSAIDs for acute local pain relief: in vitro characterization of drug delivery profiles into andthrough human skin. Drug Dev Ind Pharm. 2021. doi:10.1080/03639045.2021.1935996.
7. Singh P, Roberts MS. Skin permeability and local tissue concentrations of nonsteroidalanti-inflammatory drugs after topical application. J Pharm Sci. 1997;86 (10):1108-1112.
8. Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation,diclofenac epolamine. Expert Opin Pharmacother. 2008;9 (15):2705-2716.
9. Scientific and technological prospection on transdermal formulations and complementarytherapies for the treatment of primary dysmenorrhea. Expert Rev Clin Pharmacol. 201 9;12 (2):1 65-174 . doi:10.1 080/17 51243 3.201 9.156 1284.
10. World Health Organization. WHO guideline on self-care interventions for health and well-being:2022 revision. Geneva: World Health Organization; 2022.
11. International Council for Harmonisation. ICH harmonised guideline Q8 (R2): pharmaceuticaldevelopment. Geneva: ICH; 2009.
12. United States Pharmacopeial Convention. General chapter<724>drug release. In: United StatesPharmacopeia and National Formulary. Rockville, MD: USP Convention.
13. United States Pharmacopeial Convention. General chapter<911>viscosity—capillary methods andrelated rheological considerations. In: United States Pharmacopeia and National Formulary. Rockville, MD: USP Convention.
14. Barry BW. Dermatological formulations: percutaneous absorption. New York: Marcel Dekker;198 3.
15. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56 (5):603-618.doi:10.1 016/j .addr.2 003.1 0.025 .
16. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26 (11):1261-1268.doi:10.1038/nbt.1504.
17. Kalia YN, Guy RH. Modeling transdermal drug release. Adv Drug Deliv Rev. 2001;48 (2-3):159-172.
18. Benson HAE. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv.200 5;2 (1):23 -33.
19. Dawid-Pać R, et al. Primary dysmenorrhea: pathophysiology and current pharmacologicaltreatment approaches. J Clin Med. 2023;12 (6):2205.
20. American College of Obstetricians and Gynecologists. Dysmenorrhea and endometriosis in theadolescent. Committee Opinion No. 760. Obstet Gynecol. 2018;132:e249-e258.

HOW TO CITE: Vedika Hangargi, Sakshi Suvarna, Farha Ansari, Allen Mokle, Shraddha Joshi, Diclofenac Sodium Transdermal Patches for Primary Dysmenorrhea: Formulation Strategies, Skin Permeation, and Evidence Gaps , Int. J. of Pharm. Sci., 2026, Vol 4, Issue 11, 4631-4637. https://doi.org/10.5281/zenodo.24528241